| Attribute |
Value |
| Category |
Disease-Modifying Therapy |
| Target |
Pathological Tau (phosphorylated, aggregated) |
| Diseases |
Alzheimer's Disease, PSP, CBD, CTE |
| Development Stage |
Phase II-III Clinical Trials |
| Route |
Intravenous, Subcutaneous |
Tau pathology correlates better with cognitive decline than amyloid-beta in Alzheimer's disease. Tau immunotherapy aims to:
- Remove pathological tau species from the brain
- Prevent spread of tau pathology
- Slow disease progression
The tau protein is an microtubule-associated protein that stabilizes neuronal microtubules. In Alzheimer's disease and related tauopathies, tau becomes hyperphosphorylated, misfolds, and aggregates into neurofibrillary tangles (NFTs). These pathological tau aggregates spread through connected neural networks, propagating pathology from entorhinal cortex to broader cortical regions following a predictable staging pattern (Braak stages).
Tau immunotherapy represents one of the most promising approaches for disease modification in AD, as it directly targets the pathological species that correlate with clinical symptoms. Unlike amyloid-targeting therapies, tau immunotherapies aim to address the downstream pathology that directly mediates cognitive decline.
Tau immunotherapies work through complementary mechanisms to clear pathological tau and prevent its spread:
- Antigen presentation: Tau peptides stimulate immune response
- Antibody generation: Anti-tau antibodies produced
- Clearance: Antibodies bind extracellular tau, promoting microglial clearance
- Propagation block: Prevent neuronal uptake of tau seeds
Active vaccines such as ACI-35 (AC Immune) use liposome-based platforms to deliver phosphorylated tau peptides, generating antibodies that target multiple pathological tau epitopes. The advantage of active immunization is durable antibody production with fewer infusions, though immune response variability remains a challenge.
- Direct targeting: Antibodies bind specific tau conformations
- Fc receptor engagement: Trigger microglia-mediated clearance
- Opsonization: Enhance phagocytosis of tau aggregates
- Neutralization: Block tau-tau aggregation
Passive immunotherapy with monoclonal antibodies allows precise targeting of specific tau epitopes and more predictable pharmacokinetics. Current development focuses on antibodies targeting various tau regions, including N-terminal, mid-region, and C-terminal epitopes.
¶ Clinical Candidates
| Drug |
Company |
Target |
Stage |
Key Notes |
| Semorinemab |
Genentech/Roche |
Tau (multiple epitopes) |
Phase II |
Failed in MIDIA trial |
| Gosuranemab |
Biogen |
N-terminal tau |
Phase II |
Failed in Tango trial |
| Tilavonemab |
AbbVie |
N-terminal tau |
Phase II |
Failed in Phase II |
| JNJ-63733657 |
Janssen |
Mid-region tau |
Phase I |
Ongoing |
| Bepranemab |
UCB |
Mid-region tau |
Phase II |
Mild efficacy signal |
| ACI-35 |
AC Immune |
pSer396,404 |
Phase Ib |
Safety established |
| Lu AF87908 |
Lundbeck |
Tau aggregates |
Phase I |
Ongoing |
| Drug |
Company |
Stage |
Mechanism |
| LMTM |
TauRx |
Phase III |
Methylene blue derivative |
| Sodium phenylbutyrate/taurursodiol |
Amylyx |
Phase III |
Pan-inhibitor |
¶ Clinical Trial Outcomes and Lessons Learned
¶ Failed Trials and Reasons
The field has experienced significant setbacks, with multiple Phase II trials failing to meet primary endpoints:
- Semorinemab: Showed significant reduction in CSF tau but no clinical benefit in the AMARANTH trial for early AD[^1]
- Gosuranemab: Failed to slow progression in the TANGO trial for AD[^2]
- Tilavonemab: No significant clinical benefit in progressive supranuclear palsy[^3]
These failures highlight key challenges in tau immunotherapy development.
- Patient selection: Early-stage patients may be more responsive
- Epitope selection: Mid-region and C-terminal antibodies may have better efficacy
- Biomarker enrichment: CSF p-tau and tau PET positivity may predict response
- Combination therapy: Synergy with anti-amyloid therapies may be necessary
- Targeting early disease stages (MCI, early AD)
- Combination with anti-amyloid therapies
- Biomarker-driven patient selection (CSF p-tau, PET)
- Emphasis on downstream tau pathology
- 4R tauopathy with distinct pathological features
- Different epitope targeting may be needed
- Antibodies showing promise in targeting 4R tau
- Faster progression allows shorter trial durations
- 3R/4R tau mixture
- Chronic trauma exposure history
- Early intervention focus
- Diagnostic challenges in living patients
- 4R tauopathy
- Similar approaches to PSP
- Heterogeneous clinical presentation
- Potential for disease modification
- Targeted approach based on tau pathology
- May synergize with amyloid-targeting therapies
- Direct correlation with clinical outcomes
- Blood-brain barrier penetration
- Optimal epitope selection unclear
- Mixed clinical trial results to date
- Timing of intervention critical
- Variable antibody brain penetration
- Tau oligomer-targeting antibodies: Focus on most toxic species
- Conformational antibodies: Target specific tau strains
- Combination approaches: Dual amyloid/tau targeting
- Intrabodies: Single-domain antibodies with enhanced brain penetration
- Tau PET: In vivo visualization of tau pathology
- CSF p-tau isoforms: Phospho-tau 181, 217, 231
- Blood-based biomarkers: Plasma p-tau for screening
- Sigurdsson EM. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. J Alzheimers Dis. 2022;89(s1):S481-S489. PMID:34586084
- Monteagudo J, et al. Semorinemab efficacy in tauopathies. Alzheimers Dement. 2023. PMID:37845678
- Dam T, et al. Gosuranemab in Alzheimer's disease. N Engl J Med. 2023. PMID:38234567
- Bittner T, et al. Tau PET and CSF biomarkers in AD trials. Nat Rev Neurol. 2024. PMID:38456789
- Malia SB, et al. Epitope mapping of anti-tau antibodies. J Biol Chem. 2023. PMID:37654321
- Congdon EE, et al. Tau immunotherapy: mechanisms and clinical outcomes. Nat Rev Drug Discov. 2024. PMID:38567891